These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23381781)

  • 1. A novel convergent synthesis of the antiglaucoma PGF2α analogue bimatoprost.
    Dams I; Chodyński M; Krupa M; Pietraszek A; Zezula M; Cmoch P; Kosińska M; Kutner A
    Chirality; 2013 Mar; 25(3):170-9. PubMed ID: 23381781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies.
    Dams I; Wasyluk J; Prost M; Kutner A
    Prostaglandins Other Lipid Mediat; 2013; 104-105():109-21. PubMed ID: 23353557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of prostaglandin analogues, latanoprost and bimatoprost, using organocatalysis via a key bicyclic enal intermediate.
    Prévost S; Thai K; Schützenmeister N; Coulthard G; Erb W; Aggarwal VK
    Org Lett; 2015 Feb; 17(3):504-7. PubMed ID: 25582321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost.
    Krupa M; Chodyński M; Ostaszewska A; Cmoch P; Dams I
    Molecules; 2017 Jan; 22(2):. PubMed ID: 28146132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue.
    Hellberg MR; Ke TL; Haggard K; Klimko PG; Dean TR; Graff G
    J Ocul Pharmacol Ther; 2003 Apr; 19(2):97-103. PubMed ID: 12804054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).
    Woodward DF; Krauss AH; Chen J; Liang Y; Li C; Protzman CE; Bogardus A; Chen R; Kedzie KM; Krauss HA; Gil DW; Kharlamb A; Wheeler LA; Babusis D; Welty D; Tang-Liu DD; Cherukury M; Andrews SW; Burk RM; Garst ME
    J Pharmacol Exp Ther; 2003 May; 305(2):772-85. PubMed ID: 12606640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimatoprost and its free acid are prostaglandin FP receptor agonists.
    Sharif NA; Williams GW; Kelly CR
    Eur J Pharmacol; 2001 Dec; 432(2-3):211-3. PubMed ID: 11740958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostamides (prostaglandin-ethanolamides) and their pharmacology.
    Woodward DF; Liang Y; Krauss AH
    Br J Pharmacol; 2008 Feb; 153(3):410-9. PubMed ID: 17721551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles.
    Chen J; Senior J; Marshall K; Abbas F; Dinh H; Dinh T; Wheeler L; Woodward D
    Br J Pharmacol; 2005 Feb; 144(4):493-501. PubMed ID: 15678094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS.
    Koda N; Tsutsui Y; Niwa H; Ito S; Woodward DF; Watanabe K
    Arch Biochem Biophys; 2004 Apr; 424(2):128-36. PubMed ID: 15047184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro.
    Davies SS; Ju WK; Neufeld AH; Abran D; Chemtob S; Roberts LJ
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):45-54. PubMed ID: 12648303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics.
    Woodward DF; Wang JW; Poloso NJ
    Pharmacol Rev; 2013; 65(4):1135-47. PubMed ID: 23893067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flare-up rates with bimatoprost therapy in uveitic glaucoma.
    Fortuna E; Cervantes-Castañeda RA; Bhat P; Doctor P; Foster CS
    Am J Ophthalmol; 2008 Dec; 146(6):876-82. PubMed ID: 19027422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost.
    Komoto J; Yamada T; Watanabe K; Woodward DF; Takusagawa F
    Biochemistry; 2006 Feb; 45(7):1987-96. PubMed ID: 16475787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
    Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
    Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells.
    Spada CS; Krauss AH; Woodward DF; Chen J; Protzman CE; Nieves AL; Wheeler LA; Scott DF; Sachs G
    Exp Eye Res; 2005 Jan; 80(1):135-45. PubMed ID: 15652534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.